Effect of short-term administration of cinnamon on blood pressure in patients with prediabetes and type 2 diabetes

Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: .
Nutrition (Impact Factor: 2.93). 07/2013; 29(10). DOI: 10.1016/j.nut.2013.03.007
Source: PubMed


The aim of this study was to systematically review and evaluate the effect of short-term administration of cinnamon on blood pressure regulation in patients with prediabetes and type 2 diabetes by performing a meta-analysis of randomized, placebo-controlled clinical trials.
Medical literature for randomized controlled trials (RCTs) of the effect of cinnamon on blood pressure was systematically searched; three original articles published between January 2000 and September 2012 were identified from the MEDLINE database and a hand search of the reference lists of the articles obtained through MEDLINE. The search terms included cinnamon or blood pressure or systolic blood pressure (SBP) or diastolic blood pressure (DBP) or diabetes. A random effects model was used to calculate weighted mean difference and 95% confidence intervals (CI).
The pooled estimate of the effect of cinnamon intake on SBP and DBP demonstrated that the use of cinnamon significantly decreased SBP and DBP by 5.39 mm Hg (95% CI, -6.89 to -3.89) and 2.6 mm Hg (95% CI, -4.53 to -0.66) respectively.
Consumption of cinnamon (short term) is associated with a notable reduction in SBP and DBP. Although cinnamon shows hopeful effects on BP-lowering potential, it would be premature to recommend cinnamon for BP control because of the limited number of studies available. Thus, undoubtedly a long-term, adequately powered RCT involving a larger number of patients is needed to appraise the clinical potential of cinnamon on BP control among patients with type 2 diabetes mellitus.

Download full-text


Available from: Nicola Robinson,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cinnamaldehyde (CA), a major component of cinnamon, is known to have important actions in the cardiovascular system, including vasorelaxation and decrease in blood pressure. Although CA-induced activation of the chemosensory cation channel TRPA1 seems to be involved in these phenomena, it has been shown that genetic ablation of Trpa1 is insufficient to abolish CA effects. Here, we confirm that CA relaxes rat aortic rings and report that it has negative inotropic and chronotropic effects on isolated mouse hearts. Considering the major role of L-type Ca(2+) channels in the control of the vascular tone and cardiac contraction, we used whole-cell patch-clamp to test whether CA affects L-type Ca(2+) currents in mouse ventricular cardiomyocytes (VCM, with Ca(2+) as charge carrier) and in mesenteric artery smooth muscle cells (VSMC, with Ba(2+) as charge carrier). We found that CA inhibited L-type currents in both cell types in a concentration-dependent manner, with little voltage-dependent effects. However, CA was more potent in VCM than in VSMC and caused opposite effects on the rate of inactivation. We found these divergences to be at least in part due to the use of different charge carriers. We conclude that CA inhibits L-type Ca(2+) channels and that this effect may contribute to its vasorelaxing action. Importantly, our results demonstrate that TRPA1 is not a specific target of CA and indicate that the inhibition of voltage-gated Ca(2+) channels should be taken into account when using CA to probe the pathophysiological roles of TRPA1.
    Pflügers Archiv - European Journal of Physiology 02/2014; 466(11). DOI:10.1007/s00424-014-1472-8 · 4.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pathogenesis of neurodegenerative diseases involves complex interactions between multiple mechanisms, including but not limited to oxidative stress, inflammation, and proteotoxicity, which have yet to be ameliorated by pharmaceutical drugs with single targets. Natural products have been recognized for their health promoting effects for thousands of years. Plants produce a vast collection of secondary products, such as alkaloids, phenolic compounds, and terpenes that have shown health benefits in a variety of conditions including cancer, cardiovascular disease, and neurodegenerative diseases. In the search for more effective and safe treatment options for neurodegenerative diseases, several dietary sources of phytochemicals have been investigated. Historical usage in traditional medicine, along with modern research has identified several key products with potential benefits in neurodegenerative diseases. Among the dietary sources, cinnamon shows particular merit as a therapeutic potential for neurodegenerative diseases. Accumulating evidence suggesting neuroprotective effects via modulation of various risk factors relevant to neurodegeneration has been reviewed here. Industrial relevance. Cinnamon has been cherished for its health-promoting effects for thousands of years. Today, while modern medicine provides critical pharmaceutical agents that have assisted in ameliorating many diseases and extended the average lifespan significantly in the past century, these agents are associated with many side effects and expenses. As such, the search for efficient therapies with limited side effects is a significant target of research. Cinnamon, as a rich source of phytochemicals and long history in traditional medicine, has been a popular spice in recent decades for investigations elucidating its health-promoting effects. This review evaluates the therapeutic potential of cinnamon in ameliorating the risk factors responsible for the development of neurodegenerative diseases and associated pathologies.
    International Journal of Applied Research in Natural Products 01/2015; 8(3):24-46.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This randomised controlled trial assessed the acute and long-term effects of daily supplementation of kanuka honey, formulated with cinnamon, chromium and magnesium on glucose metabolism, weight and lipid parameters in individuals with type 2 diabetes. Twelve individuals with type 2 diabetes received 53.5 g of a formulated honey and a control (non-formulated) kanuka honey in a random order for 40 days, using cross-over design. Fasting glucose, insulin, HbA1c, lipids and anthropometric measures were measured at baseline and end of treatment. A meal tolerance test was performed at baseline to assess acute metabolic response. There was no statistically significant difference in acute glucose metabolism between treatment groups, as measured by the Matsuda index and AUC for glucose and insulin. After the 40-day intervention with honey, fasting glucose did not differ significantly between the two treatments (95 % CI -2.6 to 0.07). There was no statistically significant change in HbA1c or fasting insulin. There was a statistically significant reduction in total cholesterol by -0.29 mmol/L (95 % CI -0.57 to -0.23), LDL cholesterol by -0.29 mmol/L (95 % CI -0.57 to -0.23) and weight by -2.2 kg (95 % CI -4.2 to -0.1). There was a trend towards increased HDL and reduced systolic blood pressure in the intervention treatment. The addition of cinnamon, chromium and magnesium supplementation to kanuka honey was not associated with a significant improvement in glucose metabolism or glycaemic control in individuals with type 2 diabetes. Use of the formulated honey was associated with a reduction in weight and improvements in lipid parameters, and should be investigated further.
    European Journal of Nutrition 05/2015; DOI:10.1007/s00394-015-0926-x · 3.47 Impact Factor
Show more